The evidence from a study by Xu et al. has confirmed that immunity-related GTPase M (IRGM) as a member of the GTPases family is highly expressed in glioma, and it significantly increases the expression of P62, necrosis factor receptor activating factor 6 (TRAF6), and NF-kB transportation to the nucleus. Here, IRGM is linked to central nervous system cancer.